Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Effect of discontinuation of inhaled fluticasone propionate on exacerbations in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 183s Year: 2001
Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Aerosolized fluticasone propionate therapy in acute moderate exacerbations of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002
Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Comparable efficacy of ciclesonide and fluticasone propionate and lower incidence of oropharyngeal candidiasis with ciclesonide in patients with well-controlled moderate to severe persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Salmeterol 50μg bid significantly reduces moderate-severe exacerbations in patients with all severities of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 68s Year: 2003
Efficacy of high-dose inhaled fluticasone propionate in Indian patients having moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002
Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Survival in COPD patients after regular use of fluticasone propionate and salmeterol Source: Eur Respir J 2003; 21: 559-560 Year: 2003
Asthma total costs reduction and clinical improvement after inhaled steroid shift to fluticasone propionate during 1 year in patients with moderate to severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 56s Year: 2002
Improvements in FEV1 and symptoms in poorly-reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003
Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice Source: Eur Respir J 2001; 18: Suppl. 33, 348s Year: 2001
Inhalation of fluticasone propionate spray compared with theophilline as primary treatment for chronic mild to moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 500s Year: 2006
Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 512s Year: 2004
Efficacy and safety of ciclesonide compared with fluticasone propionate or budesonide in adolescent patients with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 458s Year: 2007